CDX2 and neoplasm: As the detection rate of CK20-positive circulating tumour cells (CK20 pCTCs) in CRC was only 62% (Wong et al, 2009), we aimed to improve the sensitivity for CRC by detecting another intestinal-type differentiation marker, CDX2 pCTCs, using the same methodology.